Theravance Biopharma(TBPH) - 2025 Q2 - Quarterly Results

YUPELRI (revefenacin) inhalation solution, the first and only once-daily, nebulized LAMA (long-acting muscarinic antagonist) bronchodilator approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD): In the US, Viatris is leading the commercialization of YUPELRI, and the Company co-promotes the product under a profit and loss sharing arrangement (65% to Viatris; 35% to the Company). Source: Viatris Customer Demand (Q2'25). Source: IQVIA DDD, HDS, VA and No ...